Open AccessBringing the first therapy to market for primary hyperoxaluria type 1: an interview with Pritesh Gandhi
Author(s) -
Pritesh J. Gandhi
Publication year - 2021
Language(s) - English
Resource type - Journals
ISSN - 2399-5262
DOI - 10.2217/frd-2021-0004
Subject(s) - vice president , pharmacy , management , public relations , political science , business , medicine , medical education , nursing , economics
Bio Dr Pritesh Gandhi joined Alnylam in 2014 and is currently Vice President and General Manager of the lumasiran program, where he leads overarching strategic and operational plans and manages the preparation and communication of relevant strategic updates of the program to multiple stakeholders. Before joining Alnylam, he served as Associate Vice President of Global Medical Affairs at Sanofi Oncology, where he spearheaded and executed on global publication, medical education and medical communication strategies. He also previously worked at Alexion Pharmaceuticals and Millennium Pharmaceuticals. Pritesh began his career as an Assistant Professor of Pharmacy at the Massachusetts College of Pharmacy and Health Sciences.